171 related articles for article (PubMed ID: 25156682)
41. Pathological Complete Response as Outcome Modifier in Breast Cancer Patients and Brain Metastasis.
Kumar U; Mishra AK; Singh KR; Raja N; Bhat G; Sooraj R; Ramakant P
Indian J Surg Oncol; 2024 Jun; 15(2):332-340. PubMed ID: 38741647
[TBL] [Abstract][Full Text] [Related]
42. The role of ultrasonographic findings for
Li S; Zhang QL; Guo RJ
Open Med (Wars); 2023; 18(1):20230725. PubMed ID: 38025526
[TBL] [Abstract][Full Text] [Related]
43. CSCO expert consensus on the diagnosis and treatment of breast cancer brain metastasis.
Wang T; Chen J; Yang J; Fu M; Hua W; Jia W; Liu Y; Wang B; Yan M; Zhou J; Hao C; Chen J; Ou D; Jiang T; Mao Y; Jiang Z; ;
Transl Breast Cancer Res; 2022; 3():22. PubMed ID: 38751521
[TBL] [Abstract][Full Text] [Related]
44. Frequent Amplification and Overexpression of PSMA in Basallike Breast Cancer from Analysis of The Cancer Genome Atlas.
Zhou W; Halder S; Herwald S; Ghijsen M; Shafi G; Uttarwar M; Rosen E; Franc B; Kishore S
J Nucl Med; 2024 Apr; ():. PubMed ID: 38664014
[TBL] [Abstract][Full Text] [Related]
45. Hormone receptor conversion in metastatic breast cancer.
Procházková K; Vojtíšek R; Vodička J; Horová J; Hošek P; Skála M; Šebek J; Dostál J; Přibáň V; Pivovarčíková K; Hes O; Třeška V; Moláček J
Rep Pract Oncol Radiother; 2023; 28(6):746-755. PubMed ID: 38515821
[TBL] [Abstract][Full Text] [Related]
46. Editorial for "Potential Antihuman Epidermal Growth Factor Receptor 2 Target Therapy Beneficiaries: The Role of MRI-Based Radiomics in Distinguishing Human Epidermal Growth Factor Receptor 2-Low Status of Breast Cancer".
Geitung JT
J Magn Reson Imaging; 2023 Nov; 58(5):1615-1616. PubMed ID: 36744580
[No Abstract] [Full Text] [Related]
47. Evaluating the natural growth rate of metastatic cancer to the brain.
Kobets AJ; Backus R; Fluss R; Lee A; Lasala PA
Surg Neurol Int; 2020; 11():254. PubMed ID: 33024592
[TBL] [Abstract][Full Text] [Related]
48. A biologically "old" breast cancer subtype in a very young woman: a plea of ignorance.
Sniadecki M; Krajewska M; Stasiak M; Walkiewicz A; Guzik PW
Ginekol Pol; 2023; 94(12):1032-1033. PubMed ID: 37417379
[No Abstract] [Full Text] [Related]
49. RARRES2's impact on lipid metabolism in triple-negative breast cancer: a pathway to brain metastasis.
Shubhra QTH
Mil Med Res; 2023 Sep; 10(1):42. PubMed ID: 37700352
[No Abstract] [Full Text] [Related]
50. Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer.
Ríos-Hoyo A; Cobain E; Huppert LA; Beitsch PD; Buchholz TA; Esserman L; van 't Veer LJ; Rugo HS; Pusztai L
J Clin Oncol; 2024 Apr; ():JCO2302614. PubMed ID: 38593393
[No Abstract] [Full Text] [Related]
51. Retraction Note: Copper-based metal-organic framework impedes triple-negative breast cancer metastasis via local estrogen deprivation and platelets blockade.
Wang S; Yin N; Li Y; Xiang T; Jiang W; Zhao X; Liu W; Zhang Z; Shi J; Zhang K; Guo X; Si P; Liu J
J Nanobiotechnology; 2024 May; 22(1):302. PubMed ID: 38822290
[No Abstract] [Full Text] [Related]
52. Editorial: Treatment for advanced breast cancer with brain metastases.
Yan M; Yang J
Front Oncol; 2023; 13():1268702. PubMed ID: 37771433
[No Abstract] [Full Text] [Related]
53. Breast Cancer Brain Metastases: Challenges and Opportunities.
Peereboom DM
JCO Oncol Pract; 2024 Jun; ():OP2400353. PubMed ID: 38905570
[No Abstract] [Full Text] [Related]
54. Brain metastases in breast cancer.
Niikura N; Saji S; Tokuda Y; Iwata H
Jpn J Clin Oncol; 2014 Dec; 44(12):1133-40. PubMed ID: 25320339
[TBL] [Abstract][Full Text] [Related]
55. Breast cancer brain metastases - A 12 year review of treatment outcomes.
De Ieso PB; Schick U; Rosenfelder N; Mohammed K; Ross GM
Breast; 2015 Aug; 24(4):426-33. PubMed ID: 25881974
[TBL] [Abstract][Full Text] [Related]
56. Local control of brain metastasis: treatment outcome of focal brain treatments in relation to subtypes.
Chong JU; Ahn SG; Lee HM; Park JT; Lee SA; Park S; Jeong J; Kim SI
J Breast Cancer; 2015 Mar; 18(1):29-35. PubMed ID: 25834608
[TBL] [Abstract][Full Text] [Related]
57. Brain metastasis in breast cancer: a comprehensive literature review.
Rostami R; Mittal S; Rostami P; Tavassoli F; Jabbari B
J Neurooncol; 2016 May; 127(3):407-14. PubMed ID: 26909695
[TBL] [Abstract][Full Text] [Related]
58. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients.
Duchnowska R; Jassem J; Goswami CP; Dundar M; Gökmen-Polar Y; Li L; Woditschka S; Biernat W; Sosińska-Mielcarek K; Czartoryska-Arłukowicz B; Radecka B; Tomasevic Z; Stępniak P; Wojdan K; Sledge GW; Steeg PS; Badve S
J Neurooncol; 2015 Mar; 122(1):205-16. PubMed ID: 25559688
[TBL] [Abstract][Full Text] [Related]
59. Current and emerging treatments for brain metastases.
Lin J; Jandial R; Nesbit A; Badie B; Chen M
Oncology (Williston Park); 2015 Apr; 29(4):250-7. PubMed ID: 25952487
[TBL] [Abstract][Full Text] [Related]
60. Organ-specific adaptive signaling pathway activation in metastatic breast cancer cells.
Burnett RM; Craven KE; Krishnamurthy P; Goswami CP; Badve S; Crooks P; Mathews WP; Bhat-Nakshatri P; Nakshatri H
Oncotarget; 2015 May; 6(14):12682-96. PubMed ID: 25926557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
